This difference may be related to GPA's binding to Ser332 of FXR LBD, ultimately activating CYPs and miR‐19a‐3p, exerting unique pharmacological effects in DILI treatment.[46] We established APAP and TP models of acute and chronic liver injury to explore the therapeutic effect of GPA. Here, NR1H4 is linked to injury.